Nitric Oxide Dependent and Independent Effects of Tumor Necrosis Factor-α on Cardiomyocyte Beating Activity and Signal Transduction Pathways

  • K. Werdan
  • U. Müller-Werdan
  • C. Reithmann
  • P. Boekstegers
  • R. Fuchs
  • I. Kainz
  • J. Stadler
Conference paper

Abstract

The authors are indebted to Dr. P. Fraunberger and to Prof. Dr. A. Walli (Institute for Clinical Chemistry, Klinikum Grosshadern, University of Munich) for the determination of TNFα- and soluble TNF receptor-plasma levels (see Fig. 13) and to Miss Susanne Grill and Miss Petra Ebner for expert technical assistance. This study was supported by the Deutsche Forschungsgemeinschaft (Mu 1010/1–4; Re 714–2/1; Sta 311/2–1).

Keywords

Depression Interferon Noradrenaline Cardiomyopathy Catecholamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arbustini E, Grasso M, Diegoli M, Bramerio M, Foglieni AS, Albertario M, Matinelli L, Gavazzi A, Goggi C, Campana C., (1991) Expression of tumor necrosis factor in human acute cardiac rejection: an immunohistochemical and immunoblotting study. Am J Pathol 139709–715Google Scholar
  2. Balligand J-L, Kelly RA, Marsden PA, Smith TW, Michel T (1993a) Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA 90: 347–351PubMedCrossRefGoogle Scholar
  3. Balligand J-L, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW (1993b) Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 91: 2314–2319PubMedCrossRefGoogle Scholar
  4. Basaran Y, Basaran MM, Babacan KF, Ener B, Okay T, Gök H, Özdemir M (1993) Serum tumor necrosis factor levels in acute myocardial infarction and unstable angina pectoris. Angiology 44: 332–337PubMedCrossRefGoogle Scholar
  5. Bensard DD, Banerjee A, Mclntyre RC Jr, Berens RL, Harken AH (1994) Endotoxin disrupts β-adrenergic signal transduction in the heart. Arch Surg 129: 198–205PubMedCrossRefGoogle Scholar
  6. Blick M, Sherwin SA, Rosenblum M, Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47: 2986–2989PubMedGoogle Scholar
  7. Blondel B, Roijen I, Cheneval JP (1971) Heart cells in culture: a simple method for increasing the proportion of myoblasts. Experientia 27: 356–358PubMedCrossRefGoogle Scholar
  8. Boekstegers P, Weidenhöfer S, Zell R, Pilz G, Holler E, Ertel W, Kapsner T, Redl H, Schlag G, Kaul M, Kempeni J, Stenzel R, Werdan K (1994) Repeated administration of a F(ab)2 fragment of an anti-tumor necrosis factor a monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels. Shock 1: 237–245PubMedCrossRefGoogle Scholar
  9. Brady AJB, Poole-Wilson PA, Harding SE, Warren JB (1992) Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 263: 1963–1966Google Scholar
  10. Chess-Williams RG, Sheridan DJ, Broadley KJ (1990) Arrhythmias and (adrenoceptor binding characteristics of the guinea-pig perfused heart during ischaemia and reperfusion. J Mol Cell Cardiol 22: 599–606PubMedCrossRefGoogle Scholar
  11. Chollet-Martin S, Depoix JP, Hvass U, Pansard Y, Vissuzaine C, Gougerot-Pocidalo MA (1990) Raised plasma levels of tumor necrosis factor in heart allograft rejection. Transplant Proc 22: 283–286PubMedGoogle Scholar
  12. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG (1990) Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes-impairment of signal transduction. Circ Res 67: 753–763PubMedGoogle Scholar
  13. DeMeules JE, Pigula FA, Mueller M, Raymond SJ, Gamelli RL (1992) Tumor necrosis factor and cardiac function. J Trauma 32: 686–692PubMedCrossRefGoogle Scholar
  14. Dinerman JL, Lowenstein CJ, Snyder SH (1993) Molecular mechanisms of nitric oxide regulation-potential relevance to cardiovascular disease. Circ Res 73: 217–222PubMedGoogle Scholar
  15. Eichenholz PW, Eichacker PQ, Hoffman WD, Banks SM, Parrillo JE, Danner RL, Natanson C (1992) Tumor necrosis factor challenges in canines: patterns of cardiovascular dysfunction. Am J Physiol 263: H668–H675PubMedGoogle Scholar
  16. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387–389PubMedCrossRefGoogle Scholar
  17. Foulkes R, Shaw S (1992) The cardiodepressant and vasodepressant effects of tumour necrosis factor in rat isolated atrial and aortic tissues. Br J Pharmacol 106: 942–947PubMedGoogle Scholar
  18. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B (1992) The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 90: 693–698PubMedCrossRefGoogle Scholar
  19. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF (1989) Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte ß-adrenergic responsiveness. Proc Natl Acad Sci USA 86: 6753–6757PubMedCrossRefGoogle Scholar
  20. Hegewisch S, Weh H-J, Hossfeld DK (1990) TNF-induced cardiomyopathy. Lancet 335: 294–295PubMedCrossRefGoogle Scholar
  21. Kaku T, Lakatta E, Filburn C (1991) Alpha-adrenergic regulation of phosphoinositide metabolism and protein kinase C in isolated cardiac myocytes. Am J Physiol 260: 0635–C642Google Scholar
  22. Latini R, Bianchi M, Correale E, Dinarello CA, Fantuzzi G, Fresco C, Maggioni AP, Mengozzi M, Romano S, Shapiro L, Sironi M, Tognoni G, Turato R, Ghezzi P (1994) Cytokines in acute myocardial infarction: selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-i receptor antagonist. J Cardiovasc Pharmacol 23: 1–6PubMedGoogle Scholar
  23. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236–241PubMedCrossRefGoogle Scholar
  24. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF (1990) Plasma tumor necrosis factor in patients with septic shock: mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 141: 94–97PubMedGoogle Scholar
  25. Martich GD, Boujoukos AJ, Suffredini AF (1993) Response of man to endotoxin. Immunobiology 187: 403–416PubMedCrossRefGoogle Scholar
  26. Maury CPJ, Teppo A-M (1989) Circulating tumour necrosis factor-a (cachectin) in myocardial infarction. J Intern Med 225: 333–336PubMedCrossRefGoogle Scholar
  27. Maury CPJ, Salo E, Pelkonen P (1987) Elevated circulating tumor necrosis factor-a in patients with Kawasaki disease. J Lab Clin Med 113: 651–654Google Scholar
  28. McMurray J, Abdhullah I, Dargie HJ, Shapiro D (1991) Increased concentrations of tumor necrosis factor in “cachectic” patients with severe chronic heart failure. Br Heart J 66: 356–358PubMedCrossRefGoogle Scholar
  29. Natanson C, Eichenholz PW, Danner RL, Eichacker PQ, Hoffman WD, Kuo GC, Banks SM, MacVittie TJ, Parrillo JE (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169: 823–832PubMedCrossRefGoogle Scholar
  30. Odeh M (1994) Tumor necrosis factor-a as a myocardial depressant substance. Int J Cardiol 42: 231–238CrossRefGoogle Scholar
  31. Reithmann C, Werdan K (1994) Tumor necrosis factor a decreases inositol phosphate formation and phosphatidiylinositol-bisphosphate (PIP2) synthesis in rat cardiomyocytes. Naunyn-Schmiedebergs Arch Pharmacol 349: 175–182PubMedGoogle Scholar
  32. Reithmann C, Gierschik P, Jakobs KH, Werdan K (1991a) Regulation of adenylyl cyclase by noradrenaline and tumour necrosis factor a in rat cardiomyocytes. Eur Heart J12 [Suppl F]: 139–142Google Scholar
  33. Reithmann C, Gierschik P, Werdan K, Jakobs KH (1991b) Tumor necrosis factor a up- regulates Gia and Gp proteins and adenylyl cyclase responsiveness in rat cardiomyocytes. Eur J Pharmacol - Mol Pharmacol 206: 53–60CrossRefGoogle Scholar
  34. Schulz R, Nava E, Moncada S (1992) Induction and potential biological relevance of a Ca2+- independent nitric oxide synthase in the myocardium. Br J Pharmacol 105: 575–580PubMedGoogle Scholar
  35. Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J et al. (1987) Tumor necrosis factor in man: clinical and biological observations. Br J Cancer 56: 803–808PubMedCrossRefGoogle Scholar
  36. Smith SC, Allen PM (1992) Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 70: 856–863PubMedGoogle Scholar
  37. Spriggs DR, Sherman ML, Michi H, Arthur KA, Imamura K, Wilmore D, Frei III E, Kufe DW (1988) Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study. J Natl Cancer Inst 80: 1039–1044PubMedCrossRefGoogle Scholar
  38. Squadrito F, Altavilla D, Zingarelli B, Ioculano M, Calapai G, Campo GM, Miceli A, Caputi AP (1993) Tumor necrosis factor involvement in myocardial ischaemia-reperfusion injury. Eur J Pharmacol 237: 223–230PubMedCrossRefGoogle Scholar
  39. Steinberg SF, Kaplan LM, Inouye T, Zhang JF, Robinson RB (1989) Alpha-i adrenergic stimulation of 1,4,5-inositol triphosphate formation in ventricular myocytes. J Pharmacol Exp Ther 250: 1141–1148PubMedGoogle Scholar
  40. Szabo C, Thiemermann C, Wu C-C, Perretti M, Vane JR (1994) Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA 91: 271–275PubMedCrossRefGoogle Scholar
  41. van der Poll T, van Deventer JH (1993) Tumor necrosis factor a: a common mediator of the spectrum of diverse changes in sepsis. In: Vincent J-L (ed) Yearbook of intensive care and emergency medicine 1993: Springer, Berlin Heidelberg New York, pp 84–99Google Scholar
  42. van der Poll T, Jansen J, van Leenen D, von der Mohlen M, Levi M, ten Cate H, Gallati H, ten Cate JW, van Deventer SJH (1993) Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 168: 955–960Google Scholar
  43. Vincent J-L, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E (1992) Administration of anti-TNF antibody improves left ventricular function in septic shock patients - results of a pilot study. Chest 101: 810–815PubMedCrossRefGoogle Scholar
  44. Warren JB, Pons F, Brady AJB (1994) Nitric oxide biology: implications for cardiovascular therapeutics. Cardiovasc Res 28: 25–30PubMedCrossRefGoogle Scholar
  45. Weisensee D, Bereiter-Hahn J, Schoeppe W, Low-Friedrich I (1993) Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 15: 581–587PubMedCrossRefGoogle Scholar
  46. Werdan K, Erdmann E (1989) Preparation and culture of embryonic and neonatal heart muscle cells: modification of transport activity. Methods Enzymol 173: 634–662PubMedCrossRefGoogle Scholar
  47. Werdan K, Müller U, Reithmann C (1993) “Negative inotropic cascades” in cardiomyocytes triggered by substances relevant to sepsis. In: Schlag G, Redl H (eds) Pathophysiology of shock, sepsis, and organ failure. Springer, Berlin Heidelberg New York, pp 787–833Google Scholar
  48. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H (1993) Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 22: 1897–1901PubMedCrossRefGoogle Scholar
  49. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL (1993) Cellular basis for the negative inotropic effects of tumor necrosis factor-a in the adult mammalian heart. J Clin Invest 92: 2303–2312PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • K. Werdan
  • U. Müller-Werdan
  • C. Reithmann
  • P. Boekstegers
  • R. Fuchs
  • I. Kainz
  • J. Stadler

There are no affiliations available

Personalised recommendations